Together, these data prompted the hypothesis that CD53 moderates both inflammatory and metabolic functions under duress to promote inflammatory metabolic diseases, such as insulin resistance, visceral adipose inflammation, and hepatic lipid accumulation. The gene discussed is CD53; the disease is Insulin resistance.